Compare AKBA & FPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AKBA | FPH |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 343.4M | 383.2M |
| IPO Year | 2014 | 2013 |
| Metric | AKBA | FPH |
|---|---|---|
| Price | $0.88 | $5.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $4.67 | N/A |
| AVG Volume (30 Days) | ★ 3.9M | 182.4K |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 93.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $110,020,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $11.40 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.82 | $4.60 |
| 52 Week High | $3.32 | $6.64 |
| Indicator | AKBA | FPH |
|---|---|---|
| Relative Strength Index (RSI) | 29.90 | 45.88 |
| Support Level | $0.85 | $4.91 |
| Resistance Level | $1.54 | $5.16 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 7.30 | 6.82 |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
Five Point Holdings LLC is an owner and developer of mixed-use, master-planned communities in California. It is engaged in developing new communities that, in addition to homesites, include commercial, retail, educational, and recreational elements, as well as civic areas, parks, and open spaces. Its four reportable segments are Valencia, San Francisco, Great Park, and Hearthstone. It derives the majority of revenue from the Great Park segment, which includes Great Park Neighborhoods being developed adjacent to and around the Orange County Great Park, a metropolitan park under construction in Orange County, California.